These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 37533106)

  • 41. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy.
    Xu X; Wu Y; Qian X; Wang Y; Wang J; Li J; Li Y; Zhang Z
    Adv Healthc Mater; 2022 Jan; 11(1):e2101428. PubMed ID: 34706400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages.
    Yu W; Hu C; Gao H
    Adv Drug Deliv Rev; 2021 Nov; 178():113909. PubMed ID: 34352354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer.
    Caster JM; Wang AZ
    Ther Deliv; 2017 Aug; 8(9):791-803. PubMed ID: 28825397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer nanomedicines targeting tumor extracellular pH.
    Tian L; Bae YH
    Colloids Surf B Biointerfaces; 2012 Nov; 99():116-26. PubMed ID: 22078927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Obstacles and opportunities in a forward vision for cancer nanomedicine.
    de Lázaro I; Mooney DJ
    Nat Mater; 2021 Nov; 20(11):1469-1479. PubMed ID: 34226688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Engineering lactate-modulating nanomedicines for cancer therapy.
    Chen J; Zhu Y; Wu C; Shi J
    Chem Soc Rev; 2023 Feb; 52(3):973-1000. PubMed ID: 36597879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors.
    Han X; Xu Y; Geranpayehvaghei M; Anderson GJ; Li Y; Nie G
    Biomaterials; 2020 Feb; 232():119745. PubMed ID: 31918228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
    Li S; Bennett ZT; Sumer BD; Gao J
    Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines.
    Cheng Y; Song S; Wu P; Lyu B; Qin M; Sun Y; Sun A; Mu L; Xu F; Zhang L; Wang J; Zhang Q
    Adv Healthc Mater; 2021 Sep; 10(18):e2100590. PubMed ID: 34292673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
    Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
    Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancing Tumor Penetration of Nanomedicines.
    Sun Q; Ojha T; Kiessling F; Lammers T; Shi Y
    Biomacromolecules; 2017 May; 18(5):1449-1459. PubMed ID: 28328191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted nanomedicine in cisplatin-based cancer therapeutics.
    Han Y; Wen P; Li J; Kataoka K
    J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
    Durymanov MO; Rosenkranz AA; Sobolev AS
    Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.
    Elzoghby AO; Ferrone CR; Ferrone S; Nasr ML
    Drug Discov Today; 2023 Jan; 28(1):103434. PubMed ID: 36368630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nano based drug delivery systems: recent developments and future prospects.
    Patra JK; Das G; Fraceto LF; Campos EVR; Rodriguez-Torres MDP; Acosta-Torres LS; Diaz-Torres LA; Grillo R; Swamy MK; Sharma S; Habtemariam S; Shin HS
    J Nanobiotechnology; 2018 Sep; 16(1):71. PubMed ID: 30231877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physical oncology: New targets for nanomedicine.
    Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
    Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in engineering local drug delivery systems for cancer immunotherapy.
    Abdou P; Wang Z; Chen Q; Chan A; Zhou DR; Gunadhi V; Gu Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1632. PubMed ID: 32255276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance.
    Hu M; Huang L
    Adv Drug Deliv Rev; 2022 Apr; 183():114137. PubMed ID: 35143893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.